The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females

• Status: Unknown status
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The efficacy of Solifenacin Succinate 5 mg as adjuvant therapy and levofloxacin (500 mg) for short-term treatment to reduce symptoms in patients with symptomatic non complicated urinary tract infection in females.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dr Cipto Mangunkusumo General Hospital
• Collaborators: Astellas Pharma Indonesia Inc.; Pharos Life Corporation
• Treatments: Levofloxacin; Ofloxacin; Solifenacin Succinate

Criteria

Inclusion Criteria:

• females (18-65 years old)

• dysuria in symptomatic non complicated urinary tract infection

Exclusion Criteria:

• Pediatric Patients (< 18 years old)

• geriatric Patients (> 65 years old)

• pregnant Patients

• Patients with complicated urinary tract infection

• sexually transmitted infections

• Patients with pathological abnormalities in the urinary bladder, including stone/mass

• Catheter-mounted

• Neurological diseases/disorders

• patients with allergy/hypersensitivity with Levofloxacin/Solifenacin